The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 17, 2020
Filed:
Jun. 24, 2020
Applicants:
The Usa, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
University Court of the University of Aberdeen, Aberdeen, GB;
Inventors:
Nigel H. Greig, Phoenix, MD (US);
Weiming Luo, Lutherville, MD (US);
David Tweedie, Joppa, MD (US);
Neil Vargesson, Aberdeen, GB;
Shaunna Beedie, Aberdeen, GB;
William Douglas Figg, Fairfax, VA (US);
Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 209/44 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61K 31/4035 (2006.01); A61K 31/428 (2006.01); A61K 31/431 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/536 (2006.01); A61K 45/06 (2006.01); C07D 209/48 (2006.01); C07D 209/52 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07D 499/80 (2006.01); C07D 209/46 (2006.01);
U.S. Cl.
CPC ...
C07D 209/44 (2013.01); A61K 31/4035 (2013.01); A61K 31/428 (2013.01); A61K 31/431 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/536 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C07D 209/46 (2013.01); C07D 209/48 (2013.01); C07D 209/52 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 499/80 (2013.01);
Abstract
Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.